2010: June

Started trading on Nasdaq Global Market (JGBO) 

2009: April

Company name changed to Jiangbo Pharmaceuticals, Inc. (OTCBB: JGBO)

2009: January

Entered into agreement to purchase Hongrui Pharmaceuticals, and to acquire 22 new Traditional Chinese Medicines

2008: September 

Completed a 40-for-1 reverse stock split of its common stock which will begin trading under the symbol “GNPH.”

2008: July

Got SFDA approval for the production of Radix Isatidis Dispersible Tablets

2008: May

Completed a $30 million private note placement

2007: December

Launched Baobaole Chewable tablets.

2007: November

Completed a $5 million private placement with Pope Investments, LLC

2007: October

Laiyang Jiangbo and Genesis Technology undertook a reverse merger to emerge as a public OTC company - Genesis Pharmaceuticals Enterprises, Inc.

2006

Laiyang Jiangbo launched Clarithromycin sustained-released tablets.

2005

Laiyang Jiangbo launched Itopride Hydrochloride granules.

2004

Laiyang Jiangbo launched Ciprofloxacin Hydrochloride tablets&Paracetamol tablets.

2003

Laiyang Jiangbo Pharmaceuticals Company Limited founded in Laiyang City, Shandong Province, the PRC.

2001

Genesis Technology Group, Inc. founded in the State of Florida, the U.S.